UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  November 12, 2024

AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
000-50761
 11-3146460
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

14 Plaza Drive Latham, New York
  
12110
Address of Principal Executive Offices)
  
(Zip Code)

(518) 795-1400

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock, par value $0.01 per share
 ANGO
   NASDAQ Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
(e)
As described below, the shareholders of AngioDynamics, Inc. (“AngioDynamics”) voted on November 12, 2024 to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan (the “2020 Plan”) to increase the number of shares available for issuance. The material terms of the 2020 Plan are described in Proposal 4 included in AngioDynamics’ definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024, which description does not purport to be complete and is qualified in its entirety by reference to the full text of the 2020 Plan, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 5.07
Submission of Matters to a Vote of Security Holders.

(a)
The Annual Meeting of Shareholders of AngioDynamics was held on November 12, 2024.

(b)
Shareholders of AngioDynamics voted on the matters set forth below.

1.
The nominees for election to the Board of Directors were elected, each as a Class III director to serve until the 2027 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes:

Nominee
Votes For
Withheld
Broker Non-Votes
Lorinda A. Burgess
26,292,870
1,996,095
5,993,164
Wesley E. Johnson, Jr.
24,817,356
3,471,609
5,993,164
Karen A. Licitra
26,276,748
2,012,217
5,993,164

2.
The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2025 was approved based upon the following votes:

Votes for approval
34,110,530
Votes against
155,077
Abstentions
16,522

There were no broker non-votes for this item.
3.
The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation of its named executive officers was approved based upon the following votes:

Votes for approval
26,004,908
Votes against
1,248,479
Abstentions
1,035,578
Broker non-votes
5,993,164

4.
The proposal to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan was approved based upon the following votes:

Votes for approval
23,195,346
Votes against
5,058,468
Abstentions
35,151
Broker non-votes
5,993,164

(c)
Not applicable.

(d)
Not applicable.

Item 9.01
Financial Statements and Exhibits.

(d)
Exhibits.

Exhibit No.
Description
   
AngioDynamics, Inc. 2020 Equity Incentive Plan, as amended (incorporated by reference to Appendix A of the Registrant’s Definitive Proxy Statement filed on September 26, 2024 in connection with the Annual Meeting held on November 12, 2024 (File No. 000-50761)).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
ANGIODYNAMICS, INC.
 
(Registrant)
   
Date: November 15, 2024
By:  /s/ Stephen A. Trowbridge
 
Name:  Stephen A. Trowbridge
 
Title:  Executive Vice President and Chief Financial Officer


v3.24.3
Document and Entity Information
Nov. 12, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 12, 2024
Entity File Number 000-50761
Entity Registrant Name AngioDynamics, Inc.
Entity Central Index Key 0001275187
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 11-3146460
Entity Address, Address Line One 14 Plaza Drive
Entity Address, City or Town Latham
Entity Address, State or Province NY
Entity Address, Postal Zip Code 12110
City Area Code 518
Local Phone Number 795-1400
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol ANGO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
AngioDynamics (NASDAQ:ANGO)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025 Haga Click aquí para más Gráficas AngioDynamics.
AngioDynamics (NASDAQ:ANGO)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025 Haga Click aquí para más Gráficas AngioDynamics.